# Data Sheet (Cat.No.T39585)

TargetMol

## Ziftomenib

### Chemical Properties



CAS No. : 2134675-36-6

Formula: C33H42F3N9O2S2

Molecular Weight: 717.871

Storage: Keep away from direct sunlight,Keep away from moisture,Store under nitrogen
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

### Biological Description

| | |
|---|---|
| Description | Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity, suitable for leukemia research. |
| Targets(IC50) | Epigenetic Reader Domain,Histone Methyltransferase |
| In vitro | Zifomenib acts highly selective in MLL-r and NPM1mut acute myeloid leukemia and synergizes with a variety of targeted drugs in vitro[1]. |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 80 mg/mL (111.44 mM),Sonification is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (4.6 mM),Sonication is recommended.<br>*Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.* |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 1.393 mL | 6.965 mL | 13.9301 mL |
| 5 mM | 0.2786 mL | 1.393 mL | 2.786 mL |
| 10 mM | 0.1393 mL | 0.6965 mL | 1.393 mL |
| 50 mM | 0.0279 mL | 0.1393 mL | 0.2786 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Rausch J, et al. Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Haematologica. 2023 Oct 1;108(10):2837-2843.